

<p>Informazione Regolamentata n. 0957-14-2024</p>	<p>Data/Ora Inizio Diffusione 15 Marzo 2024 17:02:41</p>	<p>Euronext Milan</p>
---	--	-----------------------

Societa' : DIASORIN

Identificativo Informazione Regolamentata : 187477

Utenza - Referente : DIASORINN01 - Ulisse Spada - Valerio Giovanni Vaccarone

Tipologia : 3.1

Data/Ora Ricezione : 15 Marzo 2024 17:02:41

Data/Ora Inizio Diffusione : 15 Marzo 2024 17:02:41

Oggetto : Diasorin: Publication of the documents for the Ordinary Shareholders' Meeting scheduled on April 24, 2024

*Testo del comunicato*

See attachment.

## **DIASORIN: PUBLICATION OF THE DOCUMENTS FOR THE ORDINARY SHAREHOLDERS' MEETING SCHEDULED ON APRIL 24, 2024**

**Saluggia, March 15, 2024** – In relation to the ordinary shareholders' meeting of DiaSorin S.p.A. (FTSE MIB: DIA) convened in a single call on April 24, 2024, at 2:30 p.m. CET, it is announced that - in compliance with the applicable legal requirements – today the Company has made available at its registered office, on its website (<https://int.diasorin.com>, Section “Company/Governance/Shareholders’ Meeting/2024”) and on the on the authorized central storage mechanism “eMarketStorage” ([www.emarketstorage.com](http://www.emarketstorage.com)):

- the Explanatory Reports on the items on the agenda,
- the proxy forms pursuant section 125-*novies* and 135-*undecies* of Legislative Decree 58/1998;
- the Report on the Remuneration Policy and Fees Paid.

The remaining documents related to the Shareholders’ Meeting, including the documents provided under article 154-ter of Legislative Decree 58/1998, will be made available within the terms and according to the modalities set forth by the law.

### **About DiaSorin**

Headquartered in Italy and listed at the Italian Stock Exchange in the FTSE MIB Index, DiaSorin is a global leader in the In Vitro Diagnostic (IVD) field and is active since 2021 in the Life Science business. For over 50 years, the Company has been developing, producing and marketing reagent kits used by diagnostic laboratories worldwide.

The Group operates in 5 continents through 35 companies, 4 branches, 10 manufacturing facilities and 9 research and development centers. The extensive diagnostic testing and Life Science offer, made available through continuous investments in research, positions DiaSorin as the player with the broadest range of specialty tests available within the diagnostic market, and identifies the Group as the “Diagnostic Specialist”.

More info at [www.diasorin.com](http://www.diasorin.com)

### **FOR ADDITIONAL INFORMATION, PLEASE CONTACT:**

#### **INVESTOR RELATIONS**

##### **Riccardo Fava**

Corporate VP Communication, ESG & Investor Relations  
[riccardo.fava@diasorin.it](mailto:riccardo.fava@diasorin.it)

##### **Eugenia Ragazzo**

Corporate Investor Relations & ESG Analyst  
[eugenia.ragazzo@diasorin.it](mailto:eugenia.ragazzo@diasorin.it)

